A phase II study of docetaxel and carboplatin in Thai patients with advanced non-small-cell lung cancer

• Main Authors: Sumitra Thongprasert, Sirikul Soorraritchingchai, Busayamas Chewaskulyong, Chaiyut Charoentum, Sutthirak Munprakan
• Format: Journal
• Published: 2018
• Subjects: Medicine
• Online Access: https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=33646002331&origin=inward; http://cmuir.cmu.ac.th/jspui/handle/6653943832/61899
• Institution: Chiang Mai University

Objective: This phase II study aimed to assess the effectiveness of the docetaxel plus carboplatin combination in chemotherapy-na□ve Thai patients with advanced non-small-cell lung cancer (NSCLC). Material and Method: Forty patients with Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0-1, stage IIIB/IV NSCLC were enrolled in a phase II study between August 2001 and April 2003. Docetaxel 75 mg/m2 and Carboplatin AUC = 6 were given every 3 weeks. Response to treatment and toxicity were graded using standard WHO criteria. The Thai Functional Living Index Cancer (T-FLIC) scale was used to assess the Quality of Life (QoL) of all treated patients. Results: Forty patients (median age: 55 years, range, 39-68 years; PS:0-1) were enrolled: one had stage IIIB disease with effusion, while thirty-nine had stage IV disease. Five patients were non-evaluable due to death within the first cycle; two dying of febrile neutropenia and sepsis, two of pulmonary infection, and one of unknown etiology. Partial response (PR) was seen in 28.6% patients, stable disease (SD) in 25.7%, and progressive disease (PD) in 45.7%. The median survival time was 32 weeks and the 1-year survival rate was 30.7%. Body mass index (BMI) was the only factor associated with survival time (univariate analysis: p = 0.006; multivariate analysis: p = 0.004). Other factors (gender, age, histology, ECOG PS, and glomerular filtration rate) were not predict for survival. The major treatment-related toxicities were neutropenia (from 152 treatment cycles there were grade 4: 19.7%; grade 3: 23.7%), febrile neutropenia (from 152 treatment cycles there was 3.95%), and diarrhea (grades 3/4: 0.66%). The QoL scores improved significantly throughout the treatment period. Conclusion: The regimen of docetaxel and carboplatin is active in advanced NSCLC and may be considered for first-line therapy.